Optimi Health Up 7.8% as After Health Canada Go-Ahead to Supply MDMA and Psilocybin to Patients in Australia
Optimi Health Up 12% After Reporting Drug Establishment License From Health Canada
Optimi Health to Be Sole Supplier of Psilocybin for ATMA Journey Centers Phase II Trial
Optimi Health Notes Lykos Therapeutics and FDA Priority Review of New Drug Application
Optimi Health Secures Amendment to Increase Quantities of MDMA, MDA, and 2C-B
Optimi Health Seek Regulatory Nod for Initial Testing of Psychedelic Drug Combination
Optimi Health Reports Completion of First Production of Novel MDMA Drug Candidate OPTI-MHCL
Optimi Health Enters 3 Distribution Agreements for Optimi Life Nutraceutical Mushroom Products
Optimi Health Finalizes 3 Retail, E-Commerce Distribution Agreements
Optimi Health Signs Pact with SABI Mind For Therapeutic Supplies of Psilocybin, MDMA
Optimi Health Up 8.3% after Reporting Request to Amend Controlled Substances Dealer's Licence
Optimi Health Enters Supply Agreement with Halucenex Life Sciences
OPTEC International Receives Increased Interest In The Company's Fuel Maximizer Products Due To Record Breaking Global Fuel Price Increase
Optimi Health Begins Cultivation Of Natural Psilocybin For Use In Clinical Trials
OPTEC International Inc Announces Significant 28% Single Asset Increase of $700,000 In less than Nine Months
OPTEC INTERNATIONAL INTRODUCES Company’s New Marketplace Website
OPTEC To Debut Company's Patented Cell Phone and Tablet Digital Temperature Scanning Technology Prototypes in March 2022
OPTEC Signs Amicable Settlement with Weshield & Collaberation of PPE Sales Agreement
OPTEC Announces Surge in PPE Product Demand
Optec International, Inc Corporate Update OPTEC Cancels 30,000 Preferred Shares
No Data